Patents by Inventor Mark Kayton

Mark Kayton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule
    Publication number: 20050175980
    Abstract: A method of measuring the angiogenic or antiangiogenic activity of a test molecule comprising (i) utilizing a modified CAM assay to assign an FVD value for a test region of interest and comparing this value to an FVD value for a control region of interest, or (ii) utilizing a modified CAM assay to determine the spectrophotometric absorbance value of a test region of interest and comparing this value to the spectrophotometric absorbance value of a control region of interest, wherein a lower value of the test region of interest as compared to the of the control region of interest is indicative of the test molecule being useful as an inhibitor of angiogenesis, and wherein a higher value of the test region of interest as compared to the value of the control region of interest is indicative of the test molecule being useful as a stimulator of angiogenesis.
    Type: Application
    Filed: April 9, 2003
    Publication date: August 11, 2005
    Applicant: Government of the United States of America, repres by the Secretary, Dept. of Health and Human Serv.
    Inventors: Steven Libutti, Mark Kayton
  • Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule
    Publication number: 20050136006
    Abstract: A method of measuring the angiogenic or antiangiogenic activity of a test molecule comprising (i) utilizing a modified CAM assay to assign an FVD value for a test region of interest and comparing this value to an FVD value for a control region of interest, or (ii) utilizing a modified CAM assay to determine the spectrophotometric absorbance value of a test region of interest and comparing this value to the spectrophotometric absorbance value of a control region of interest, wherein a lower value of the test region of interest as compared to the of the control region of interest is indicative of the test molecule being useful as an inhibitor of angiogenesis, and wherein a higher value of the test region of interest as compared to the value of the control region of interest is indicative of the test molecule being useful as a stimulator of angiogenesis. Furthermore, such measurements of angiogenic or antiangiogenic activity may be monitored in an animal or patient afflicted with a disease.
    Type: Application
    Filed: December 16, 2004
    Publication date: June 23, 2005
    Applicant: Government of the U.S.A.,represented by the Secretary, Department of Health & Human Services
    Inventors: Steven Libutti, Mark Kayton
  • Endothelial monocyte activating polypeptide II: a mediator which activates host response
    Patent number: 6734168
    Abstract: The present invention provides for a purified endothelial monocyte activating polypeptide II, wherein the polypeptide has an apparent molecular weight of about 20,000 Daltons. The present invention also provides for an effector cell activating protein comprising a polypeptide having an amino acid sequence wherein at least four amino acid residues are the same as RIGRTVT and are in the same relative positions. The invention also provides for a DNA which encodes the effector cell activating protein. The invention also provides for methods of inducing inflammation in a subject and methods of treating tumors in a subject. The invention also provides for a pharmaceutical composition which comprises the endothelial monocyte activating polypeptide II and a carrier.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: May 11, 2004
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: David M. Stern, Matthias Clauss, Janet Kao, Mark Kayton, Steven K. Libutti
  • Endothelial monocyte activating polypeptide II: a mediator which activates host response
    Publication number: 20020160957
    Abstract: This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).
    Type: Application
    Filed: May 7, 2001
    Publication date: October 31, 2002
    Applicant: The Trustees of Columbia University
    Inventors: David M. Stern, Matthias Clauss, Janet Kao, Mark Kayton, Steven K. Libutti
  • Endothelial monocyte activating polypeptide II: a mediator which activates host response
    Patent number: 6228837
    Abstract: This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: May 8, 2001
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: David M. Stern, Matthias Clauss, Janet Kao, Mark Kayton, Steven K. Libutti
  • Antibody which specifically binds to endothelial-monocyte activating polypeptide II
    Patent number: 5641867
    Abstract: This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).
    Type: Grant
    Filed: September 29, 1993
    Date of Patent: June 24, 1997
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: David M. Stern, Matthias Clauss, Janet Kao, Mark Kayton, Steven K. Libutti